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Nanodosimetry is an emerging experimental technique that 
measures the so-called particle track structure, i.e. the 
pattern of ionizing radiation interaction with matter on the 
nanometric scale. In such small dimensions, comparable to 
the diameter of the DNA double helix, the stochastic nature 
of ionizing radiation interactions has to be taken into 
account. 
The stochastic quantity of nanodosimetry is the ionization 
cluster size (ICS), i.e. the number of ionizations produced by 
a passing particle within a specific nanometric target volume. 
The frequency distribution of ionization cluster size (ICSD) 
depends on the size of the target volume and its distance 
from the primary particle trajectory. The ICSD is a 
characteristic of the track structure. The statistical moments 
of the ICSD can be used to establish a new concept of 
radiation quality that is based on measurable physical 
quantities of the radiation that are closely related to the 
biological effects of the radiation. 
Three nanodosimeters of different type have been developed 
for measurement of ICSDs [1-3] in a sensitive volume of a 
dilute gas which is simulating microscopic targets based on a 
density scaling principle [4]. They are differing in the 
operating gas used, the detected particle type (electrons or 
cations of the target gas) and the size of the equivalent 
nanometric target in biological matter (a.k.a. site size). 
Within the European Project BioQuaRT [5, 6] and the adjoint 
Italian MITRA project [7], the three European nanodosimeters 
( “StarTrack“, “Ion Counter”, “Jet Counter”) [8-10] have 
been compared by measuring ion beams with all three 
nanodosimeters. 
Fig. 1 shows a synopsis of particular moments of all measured 
ICSDs. Each data point represents a measurement of a 
radiation quality (energy and type of ion) with a particular 
nanodosimeter simulating a certain nanometric site size. The 
horizontal axis is the mean ionization cluster size M1(Q), i.e. 
the number of ionizations obtained for the combination 
(indicated by Q) of radiation quality and site size. The 
vertical axis is the cumulative probability F2(Q) for obtaining 
at least two ionizations when measuring this radiation quality 
with the respective nanodosimeter. These quantities are 
obtained from the measured frequency P(v|Q) of ionization 
cluster size v. 
 
Fig. 1 
All data points shown in the Fig. 1 are falling on the same 
curve indicated by the dashed line. Similar results are also 
found when cumulative probabilities Fk for a cluster size ν ≥ k 
are plotted versus M1. Hence, despite the different operating 
principles of the nanodosimeters, there seems to be a 
universal relation between the cumulative probabilities Fk 
and the mean ionisation cluster size M1. 
The saturation behavior seen in Fig. 1 is found for all 
cumulative probabilities Fk. Hence, the universal curves have 
a similarity to the curves expected for the yields of 
radiobiological endpoints. Fig. 2 illustrates, that this 
similarity can be exploited to establish a quantitative 
correlation between nanodosimetric quantities and 
radiobiological effects. 
 
Fig. 2 
The colored data points are results from cell experiments 
using protons (blue) and carbon ions (red). The vertical axis is 
the cross section for cell inactivation determined from the 
cell survival curves at 5% survival rate [11, 12]. The 
horizontal axis is the mean ionization cluster size that was 
obtained from Monte Carlo simulations. The black data points 
are mean cluster size and cumulative probability F2 derived 
from the simulated ICSDs.  
The track structure simulations were carried out for different 
values of the nanometric site size. The data plotted in Fig. 2 
are those for which the nanodosimetric curve indicated by 
the grey line provides a best fit to the radiobiological data. 
This best fit is obtained if a site size of 1 nm in liquid water 
is used, i.e. of about half the diameter of the DNA double 
helix. 
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Brachytherapy in gynaecological cancers, and especially in 
cervix cancer, has greatly evolved during the last twenty 
years. For decades, brachytherapy has relied on x-ray 
orthogonal acquisitions, and prescription has been a matter 
of systems and schools, making reporting and comparisons 
difficult. Based on the developments of afterloaders and 
treatment planning systems, image-guided adaptive 
brachytherapy has emerged. This high precision technique 
combines all modern radiation requirements: image 
guidance, adaptation to tumor response, and short time 
treatment.  
Ten years ago, the GEC-ESTRO, in a will of harmonizing 
practices, published recommendations in cervical cancers 
regarding the definition of target-volumes and the reporting. 
These recommendations were rapidly adopted worldwide. 
During the last decade, multiple monocentric series, 
historical cohorts’ comparisons, and a prospective 
multicentric study (STIC trial) demonstrated high local 
control rates with a limited morbidity in regard to classical 
data. These data are about to be confirmed by two large 
studies led by the Gyn GEC-ESTRO: Retro-EMBRACE and 
EMBRACE, which will establish MRI-guided brachytherapy as a 
gold standard.  
In addition, clear dose-volume effect relationships have been 
demonstrated between the modern dosimetric parameters 
and the probability of achieving local control or facing 
morbidity. The better knowledge of these correlations 
allowed the launch of EMBRACE II, a prospective study 
combing the best radiation modalities (EBRT and IGABT), 
with optimal and ambitious planning aims. In the near future, 
the large amount of data collected in the EMBRACE study (> 1 
500 patients accrued) will allow the development of 
monograms integrating not only dosimetric parameters, but 
also criteria on comorbidities, clinical features, and tumor 
response to external beam radiotherapy. This would be of 
great help in adapting and personalizing treatment plans.  
Longer-term prospects include the development of 
alternative image modalities for guidance, such as endorectal 
ultrasound, cheaper and more accessible than MRI, or 
conversely, a more advanced and sophisticated image 
modality.  
Image-guided brachytherapy is also progressively declined in 
other gynecologic tumors, such as vagina cancer or non-
operable endometrial cancer. 
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Prostate brachytherapy allows radiation dose escalation 
directly into the gland with minimal dose to adjacent rectum 
and bladder. Over the last decade improvements in 
brachytherapy technology have refined dose delivery with 
the introduction of HDR after loading devices, more 
sophisticated treatment planning systems and the 
incorporation of functional imaging into the planning process. 
This teaching lecture will provide an overview of the 
techniques, indications, and clinical outcomes for both 
permanent and High Dose Rate prostate brachytherapy. 
Recent results from randomised clinical trials will be 
critiqued and emerging indications including focal and 
salvage treatments discussed. 
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Introduction: Variation in shape, position and treatment 
response of both tumour and organs at risk are major 
challenges for accurate dose delivery in radiotherapy. 
Adaptive radiotherapy (ART) has been proposed to customise 
the treatment to these motion/response patterns of the 
individual patients, but increases workload thus challenge 
clinical implementation. This presentation presents a review 
of the clinically implemented ART in addition to in silico 
workflows that have been published on pelvic tumours.  
 
Material and methods: Initial identification of papers was 
based on searches in PubMed. For each tumour site (prostate, 
gynaecological [gynae], bladder, ano-rectal), the identified 
papers were screened independently by two researches for 
selection of studies describing all processes of an ART 
workflow: treatment monitoring and evaluation, decision and 
execution of adaptations. Both brachytherapy (BT) and 
external beam studies were eligible in the review.  
 
Result: The review consisted of 43 clinical studies and 51 in 
silico studies. For prostate, 1219 patients were treated with 
offline re-planning workflows, mainly to adapt prostate 
motion relative to bony anatomy. For gynae 1155 patients 
were treated with online BT re-planning while 25 ano-rectal 
cancer patients were treated with offline re-planning, all to 
account for tumour regression detected by MRI/CT. For 
bladder and gynae, 161 and 64 patients respectively, were 
treated with library-based online plan selection to account 
for target volume and shape variations (Figure). In 
comparison to non-ART, sparing of rectum (prostate and 
bladder cancer), bladder (ano-rectal cancer) and bowel 
cavity (gynae and bladder cancer) was reported with ART. 
